Figure 1. Treatment schema of the AML-D24 study. The SR group includes patients with negative or indeterminate GATA1 mutation by Sanger sequencing, and those whose FCM-MRD is unevaluable. AZA, azacitidine; BMA, bone marrow aspiration; C, cytarabine; cC, continuous cytarabine; CET, cytarabine, etoposide, pirarubicin; CT, cytarabine, pirarubicin; CR, complete remission; E, etoposide; FCM, flow cytometry; hC, high-dose cytarabine; HR, high risk; LR, low risk; ML-DS, myeloid leukaemia of Down syndrome; MRD, measurable residual disease; MRD-HR, MRD high risk; SR, standard risk; T, pirarubicin; V, vincristine.